Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas To Develop Beta-Secretase Inhibitor For Alzheimer’s In Deal With CoMentis

This article was originally published in PharmAsia News

Executive Summary

Astellas Pharma will front $80 million, an additional $20 million equity investment and up to $660 million in development milestones for rights to CoMentis' beta-secretase inhibitor program for Alzheimer's disease

You may also be interested in...



Alzheimer's Partnerships: Sharing Risks, Chasing Potentially Huge Rewards

Even now, decades after the first scientifically informed hypotheses about what causes Alzheimer's disease (AD), no consensus and thus no clear path towards treatment exists. Offsetting the uncertainty is the knowledge that a truly effective treatment would be a smashing success - potentially generating double-digit billions in annual global revenues

Alzheimer's Partnerships: Sharing Risks, Chasing Potentially Huge Rewards

Even now, decades after the first scientifically informed hypotheses about what causes Alzheimer's disease (AD), no consensus and thus no clear path towards treatment exists. Offsetting the uncertainty is the knowledge that a truly effective treatment would be a smashing success - potentially generating double-digit billions in annual global revenues

Astellas Says It Aims for ‘Friendly’ Bid of CV Therapeutics As Q3 Profits Decline

TOKYO - An Astellas Pharma senior executive said during a Feb. 2 earnings call the company is aiming to make its bid for CV Therapeutics a friendly proposal rather than a hostile takeover

Related Content

UsernamePublicRestriction

Register

LL1132458

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel